Examination of utility of bisphosphonate to osteoporosis by ovarian insufficiency after gynecologic cancer treatment

Examination of utility of bisphosphonate to osteoporosis by ovarian insufficiency after gynecologic cancer treatment - Examination of utility of bisphosphonate to osteoporosis after gynecologic cancer treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005665

Enrollment

Registered

2011-06-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis after gynecologic cancer treatment

Interventions

Administering the bisphosphonate BENET Tablets 17.5mg once a week for two years

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Cases that diagnosed as bone loss and osteoporosis by DXA method after oophorectomy or radiation therapy for gynecologic cancer

Exclusion criteria

Exclusion criteria: 1)Cases that are impossible to measure by DXA and judge bone fractures 2)Cases that receive administering bisphosphonates before start of this examination 3)Cases that have advanced renal damage 4)Cases that have upper digestive canal disturbance 5)Cases that receive resection of stomach and wide gut 6)Cases that have previous history of hypersensitivity for elements of this medicine and other bisphosphonates 7)Cases with hypocalcemia 8)Cases that cannot keep upright or sitting positioning for 30 minutes or more when taking it

Design outcomes

Primary

Measure	Time frame
The changes of bone mineral density and biochemical markers of turnover after two years from administering beginning	—

Countries

Japan

Contacts

Public ContactSugiyama Michiyo

Gifu University Obstetrics and Gynecology

michiyo@gifu-u.ac.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026